Reuters logo
BRIEF-Audentes Therapeutics gets fast track designation for its muscle disorder drug
September 27, 2017 / 12:29 PM / 24 days ago

BRIEF-Audentes Therapeutics gets fast track designation for its muscle disorder drug

Sept 27 (Reuters) - Audentes Therapeutics Inc

* Audentes Therapeutics announces rare pediatric disease and fast track designations for AT132 for the treatment of x-linked myotubular myopathy

* Audentes Therapeutics Inc - ‍preliminary data from aspiro, phase 1/2 study of AT132, expected to be available in q4 of 2017​

* Audentes Therapeutics Inc - ‍AT132 has also received orphan drug designation from both fda and european medicines agency​ Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below